Proteasome inhibition: a new anti-inflammatory strategy

@article{Elliott2003ProteasomeIA,
  title={Proteasome inhibition: a new anti-inflammatory strategy},
  author={Peter J. Elliott and Thomas Matthias Zollner and W. -H. Boehncke},
  journal={Journal of Molecular Medicine},
  year={2003},
  volume={81},
  pages={235-245}
}
The ubiquitin-proteasome pathway has a central role in the selective degradation of intracellular proteins. Among the key proteins modulated by the proteasome are those involved in the control of inflammatory processes, cell cycle regulation, and gene expression. Consequently proteasome inhibition is a potential treatment option for cancer and inflammatory conditions. Thus far, proof of principle has been obtained from studies in numerous animal models for a variety of human diseases including… CONTINUE READING

5 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Thus far , proof of principle has been obtained from studies in numerous animal models for a variety of human diseases including cancer , reperfusion injury , and inflammatory conditions such as rheumatoid arthritis , asthma , multiple sclerosis , and psoriasis .
Thus far , proof of principle has been obtained from studies in numerous animal models for a variety of human diseases including cancer , reperfusion injury , and inflammatory conditions such as rheumatoid arthritis , asthma , multiple sclerosis , and psoriasis .
Velcade ( PS-341 ) is currently being evaluated in multiple phase II clinical trials for several solid tumor indications and has just entered a phase III trial for multiple myeloma .
Velcade ( PS-341 ) is currently being evaluated in multiple phase II clinical trials for several solid tumor indications and has just entered a phase III trial for multiple myeloma .
All Topics